PUBLICATIONS OF THE PROBIO TEAM 

PROBIO IN THE NEWS

Liquid Biopsy-Based Androgen Receptor Alterations Associated With Advanced Prostate Cancer Outcomes 

ABSTRACTS AND ORAL PRESENTATIONS AT SYMPOSIA

The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer (See paper)

78.png

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer (See paper)

78.png

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis (See paper)

28.png

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer (See paper)

20.png

Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-Resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns (See paper)

18.png

The In Vitro Stability of Circulating Tumour DNA (See paper)

1_index.png

QUICK LINKS

CONTACT US

Probio Clinical Trial Team

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet
171 77 Stockholm | Nobels väg 12 A.

 

Probio on Twitter

EMAIL: info@probiotrial.org

  • Twitter